Ironwood Pharmaceuticals (NASDAQ:IRWD) Director Sells $80,459.83 in Stock

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Director Julie Mchugh sold 21,571 shares of the stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $3.73, for a total value of $80,459.83. Following the completion of the sale, the director directly owned 250,749 shares of the company’s stock, valued at approximately $935,293.77. This represents a 7.92% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Ironwood Pharmaceuticals Price Performance

Shares of NASDAQ:IRWD traded down $0.14 during midday trading on Wednesday, hitting $3.52. The company had a trading volume of 1,628,113 shares, compared to its average volume of 3,515,933. Ironwood Pharmaceuticals, Inc. has a twelve month low of $0.62 and a twelve month high of $5.78. The stock has a market cap of $573.97 million, a price-to-earnings ratio of 5.87 and a beta of 0.25. The business’s 50-day simple moving average is $3.83 and its 200-day simple moving average is $3.88.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). Ironwood Pharmaceuticals had a net margin of 28.26% and a negative return on equity of 39.65%. The company had revenue of $106.51 million during the quarter, compared to analyst estimates of $92.11 million. As a group, sell-side analysts forecast that Ironwood Pharmaceuticals, Inc. will post 1.04 EPS for the current year.

Institutional Trading of Ironwood Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Integrated Wealth Concepts LLC lifted its holdings in Ironwood Pharmaceuticals by 21.4% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock worth $25,000 after buying an additional 3,406 shares during the last quarter. LSV Asset Management purchased a new stake in Ironwood Pharmaceuticals during the 4th quarter worth about $30,000. Captrust Financial Advisors purchased a new stake in Ironwood Pharmaceuticals during the 2nd quarter worth about $32,000. Jump Financial LLC purchased a new stake in shares of Ironwood Pharmaceuticals in the 4th quarter valued at about $34,000. Finally, DGS Capital Management LLC purchased a new stake in shares of Ironwood Pharmaceuticals in the 4th quarter valued at about $35,000.

Wall Street Analyst Weigh In

Several research firms have recently commented on IRWD. Wall Street Zen upgraded Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Sunday, May 17th. Jefferies Financial Group restated a “hold” rating and set a $3.70 price target on shares of Ironwood Pharmaceuticals in a research report on Thursday, February 26th. Citizens Jmp raised their price target on Ironwood Pharmaceuticals from $8.00 to $10.00 and gave the stock a “market outperform” rating in a research report on Thursday, February 26th. Weiss Ratings restated a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a research report on Monday, April 27th. Finally, Zacks Research lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Ironwood Pharmaceuticals has a consensus rating of “Hold” and an average target price of $6.23.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.